Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33.
Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 25, 25 | -0.08 Increased by +57.89% | -0.16 Increased by +50.00% |
| Nov 7, 24 | -0.26 Decreased by -44.44% | -0.13 Decreased by -100.00% |
| Aug 13, 24 | -0.17 Increased by +87.02% | -0.15 Decreased by -13.33% |
| May 9, 24 | -0.02 Increased by +99.27% | -0.23 Increased by +91.30% |
| Mar 28, 24 | -0.19 Decreased by -575.00% | -0.23 Increased by +17.39% |
| Nov 13, 23 | -0.18 Decreased by -700.00% | -0.25 Increased by +28.00% |
| Aug 14, 23 | -1.31 Decreased by -1.11 K% | -0.25 Decreased by -424.00% |
| May 31, 23 | -2.76 Decreased by -5.62 K% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.00 K Increased by +N/A% | -13.63 M Decreased by -60.80% | Decreased by -681.25 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -20.70 M Decreased by -150.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.67 M Increased by +62.77% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -730.00 K Increased by +92.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.47 M Decreased by -668.87% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -8.27 M Decreased by -794.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -34.02 M Decreased by -23.11 K% | Decreased by N/A% - |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.59 M Decreased by -1.27 K% | Decreased by N/A% - |